We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+2.16%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$996M
AUM Growth
-$456M
Cap. Flow
-$261M
Cap. Flow %
-26.18%
Top 10 Hldgs %
67.37%
Holding
55
New
1
Increased
2
Reduced
8
Closed
6

Top Buys

Rank Stock Value
1
ZLAB icon
Zai Lab
ZLAB
+$3.17M
2
RZLT icon
Rezolute
RZLT
+$1.63M
3
GTH
Genetron Holdings Limited ADS
GTH
+$1.22M

Top Sells

Rank Stock Value
1
NFH
New Frontier Health Corporation Ordinary Shares
NFH
+$171M
2
ASND icon
Ascendis Pharma A/S
ASND
+$27.9M
3
HRMY icon
Harmony Biosciences
HRMY
+$21.4M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$15M
5
TARS icon
Tarsus Pharmaceuticals
TARS
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 97.84%
2 Materials 2.16%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HRMY icon
1
Harmony Biosciences
HRMY
$2.06B
$200M 20.05%
4,093,785
-476,363
-10% -$21.4M
SRRA
2
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$183M 18.38%
3,329,509
-2
-0% -$105
TIL icon
3
Instil Bio
TIL
$49.2M
$57.7M 5.79%
624,339
– –
ISEE
4
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$50.4M 5.06%
5,238,634
-1,193,306
-19% -$15M
SVA
5
DELISTED
Sinovac Biotech, Ltd
SVA
$38.2M 3.83%
5,900,000
– –
ALXO icon
6
ALX Oncology
ALXO
$268M
$34.1M 3.43%
4,220,048
– –
TARS icon
7
Tarsus Pharmaceuticals
TARS
$2.57B
$33.8M 3.39%
2,312,368
-674,963
-23% -$10.1M
IMPL
8
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
$26.9M 2.7%
2,884,789
– –
GERN icon
9
Geron
GERN
$943M
$23.6M 2.37%
15,238,095
– –
VTYX
10
DELISTED
Ventyx Biosciences
VTYX
$23.5M 2.36%
1,921,726
– –
AMRS
11
DELISTED
Amyris Inc.
AMRS
$21.5M 2.16%
11,642,195
– –
COGT icon
12
Cogent Biosciences
COGT
$6.83B
$17.3M 1.74%
1,920,941
– –
KDNY
13
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$15.3M 1.53%
872,151
– –
KALV
14
DELISTED
KalVista Pharmaceuticals
KALV
$15.1M 1.52%
1,533,559
– –
CLDX icon
15
Celldex Therapeutics
CLDX
$2.78B
$15.1M 1.51%
558,636
-69,720
-11% -$2.02M
VRDN icon
16
Viridian Therapeutics
VRDN
$2.15B
$15M 1.51%
1,300,000
– –
IOBT
17
DELISTED
IO Biotech
IOBT
$14.1M 1.41%
3,015,545
– –
GTH
18
DELISTED
Genetron Holdings Limited ADS
GTH
$13.8M 1.39%
2,708,058
+237,532
+10% +$1.22M
ASND icon
19
Ascendis Pharma A/S
ASND
$16.4B
$13.6M 1.36%
146,025
-296,477
-67% -$27.9M
LEGN icon
20
Legend Biotech
LEGN
$3.69B
$13.4M 1.35%
244,375
– –
RLMD icon
21
Relmada Therapeutics
RLMD
$539M
$13.4M 1.35%
705,882
– –
ACRS icon
22
Aclaris Therapeutics
ACRS
$743M
$12.5M 1.26%
898,631
– –
VRNA
23
DELISTED
Verona Pharma
VRNA
$11.5M 1.16%
2,749,918
– –
MRUS
24
DELISTED
Merus
MRUS
$10M 1%
442,000
– –
ZLAB icon
25
Zai Lab
ZLAB
$2.1B
$9.42M 0.95%
271,528
+89,951
+50% +$3.17M
1
2 3

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
RCYC
Richard C. Young & Co Newport, Rhode Island $1.21B AUM 38.41% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return

Vivo Capital's Q2 2022 Portfolio in Review

As of Q2 2022, Vivo Capital held 55 positions worth $996M, down 31% from $1.45B the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Vivo Capital withdrew a net $261M in Q2 2022, closing 6 positions and reducing 8 holdings. Its most notable exit was New Frontier Health Corporation Ordinary Shares, an estimated $171M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 85% a quarter earlier, followed by Materials and Financials.

Against the trend, Vivo Capital opened a new position in Rezolute worth $1.58M.

  • Vivo Capital's largest Q2 2022 buy was Rezolute: 489,473 shares worth $1.58M.
  • Vivo Capital added most to Zai Lab in Q2 2022, an estimated $3.17M increase.
  • Vivo Capital's biggest Q2 2022 reduction was Ascendis Pharma A/S, cutting an estimated $27.9M.
  • Vivo Capital fully exited New Frontier Health Corporation Ordinary Shares in Q2 2022, selling an estimated $171M.
  • Vivo Capital's ten largest holdings make up 67% of its $996M portfolio in Q2 2022.
  • Vivo Capital opened 1 new position and closed 6 in Q2 2022.
  • Vivo Capital's portfolio value fell 31% quarter-over-quarter to $996M.

Based on Vivo Capital's 13F filing for Q2 2022, filed 15 Aug 2022.